US FDA Accepts for priority review application for Opdivo® (nivolumab) combined with chemotherapy as first-line treatment in metastatic gastric cancer, gastroesophageal junction cancer and oesophageal adenocarcinoma

The application is based on results from the CheckMate-649 trial, which showed addition of nivolumab to first-line FOLFOX or CapeOX was associated with an improvement in overall survival in patients whose tumours express PD-L1 with a combined positive score (CPS) ≥ 5.

Source:

Biospace Inc.